BicycleTx Limited
BCYC · Nasdaq · United Kingdom
Share price · BCYC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BCYC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Oct 2026+18.6%
Nothing announced by BCYC that day or the session before.
- 2 Oct 2026-5.1%
Nothing announced by BCYC that day or the session before.
- 24 Jul 2026-7.0%
Nothing announced by BCYC that day or the session before.
- 10 Jul 2026+5.5%
Nothing announced by BCYC that day or the session before.
- 21 Apr 2026-6.8%
- 1 Apr 2026+5.6%
Nothing announced by BCYC that day or the session before.
- 24 Mar 2026+3.7%
Nothing announced by BCYC that day or the session before.
- 18 Mar 2026-7.3%
- 13 Mar 2026-5.2%
Nothing announced by BCYC that day or the session before.
- 3 Feb 2026-7.6%
Share of unusual movement by asset
For each asset, the share of BCYC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Zelenectide pevedotinevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 18% |
| Other company news (earnings, financing, releases naming no asset) | — | 10% |
| Sessions with no dated event | — | 72% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | EphA2Peptide | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma | |
| Phase 2 | Nectin-4Peptide | Bladder / Urothelial Cancer Urothelial Carcinoma |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
January 2027 (1)
What to watch
2028 (3)
2029 (1)
March 2029 (1)
What to watch
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $34M | $33M | $470M | $10M-$40M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.6M | $41M | $510M | $50M-$50M operating cash flow | report ↗ |
| 2026-Q1 | $0.9M | $49M | $560M | $61M-$66M operating cash flow | report ↗ |
| 2025-Q3 | $12M | $58M | $649M | $59M-$71M operating cash flow | report ↗ |
| 2025-Q2 | $2.9M | $71M | $722M | $79M-$73M operating cash flow | report ↗ |
| 2025-Q1 | $10.0M | $59M | $794M | $61M-$86M operating cash flow | report ↗ |
| 2024-Q3 | $2.7M | $48M | $891M | $51M-$40M operating cash flow | report ↗ |
| 2024-Q2 | $9.4M | $40M | $962M | $40M-$45M operating cash flow | report ↗ |
| 2024-Q1 | $20M | $35M | $458M | $27M-$71M operating cash flow | report ↗ |
| 2023-Q3 | $5.3M | $40M | $573M | $50M-$1.0M operating cash flow | report ↗ |
| 2023-Q2 | $11M | $40M | $340M | $43M$34M operating cash flow | report ↗ |
| 2023-Q1 | $4.9M | $32M | $294M | $39M-$46M operating cash flow | report ↗ |
| 2022-Q3 | $3.0M | $23M | $361M | $28M-$5.9M operating cash flow | report ↗ |
| 2022-Q2 | $4.4M | $20M | $373M | $27M-$24M operating cash flow | report ↗ |
| 2022-Q1 | $3.9M | $14M | $407M | $28M-$26M operating cash flow | report ↗ |
| 2021-Q3 | $4.3M | $11M | $260M | $15M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $73M | $240M | $629M | $55M-$250M operating cash flow | report ↗ |
BicycleTx Limited reported revenue of $72.59M, up 105.8% YoY, R&D spend of $240.28M, up 38.9% YoY, cash and equivalents of $628.72M, and a net loss of $218.96M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 49 sales ($523K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-05 | Perry Jennifer Scott · Chief Operating Officer | Open-market sale | 30 | $3.57 | $107 | Form 4 |
| 2026-10-05 | Perry Jennifer Scott · Chief Operating Officer | Open-market sale | 326 | $3.78 | $1K | Form 4 |
| 2026-10-05 | Thompson Travis Alvin · Chief Financial Officer | Open-market sale | 79 | $3.57 | $282 | Form 4 |
| 2026-10-05 | Lee Kevin · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 1,638 | $3.57 | $6K | Form 4 |
| 2026-10-05 | Perry Jennifer Scott · Chief Operating Officer | Open-market sale | 80 | $3.56 | $285 | Form 4 |
| 2026-10-05 | Hannay Michael Charles Ferguson · CHIEF PROD & SUPPLY CHAIN OFF | Open-market sale | 242 | $3.57 | $864 | Form 4 |
| 2026-10-05 | Skynner Michael · CHIEF SCIENTIFIC OFFICER | Open-market sale | 503 | $3.57 | $2K | Form 4 |
| 2026-10-05 | Perry Jennifer Scott · Chief Operating Officer | Open-market sale | 326 | $3.78 | $1K | Form 4 |